Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Scrutiny of Drug Makers Abroad Faulted (Asia)

This article was originally published in PharmAsia News

Executive Summary

A preliminary report by the Government Accountability Office shows the U.S. Food and Drug Administration would inspect overseas drug manufacturers once every 13 years at its typical pace. In fact, the USFDA only has records of ever inspecting a third of the 3,249 foreign drug companies on its priority list. In 2007, the agency inspected 13 out of the 714 Chinese drug makers that may export to the U.S. Out of 410 Indian facilities that could be inspected, only 65 were observed this year. In light of these findings, U.S. pharmaceutical companies say overseas drug manufacturers should be held to domestic standards. By law, U.S. manufacturers must be inspected every two years. (Click here for more - May Require Paid Subscription

You may also be interested in...



EU Plans IP Law Shake-Up

European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by the European pharmaceutical industry federation EFPIA. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.

AZ Will Sideline ‘Lucky Mistake’ To Secure COVID-19 Vaccine Approval

A lower first dose boosted the vaccine’s efficacy result – but AstraZeneca has conceded this has to be proven in a separate trial.

Teva Plans To Appeal EU Provigil Fine

Teva plans to begin appeal proceedings, the firm has told Generics Bulletin, after being fined €60.5m ($72m) by the European Commission over an historic “pay-for-delay” arrangement covering subsidiary firm Cephalon’s Provigil (modafinil).

UsernamePublicRestriction

Register

LL1134885

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel